Boehringer Ingelheim: Hepatitis C, Chronic trials

The registry lists 18 Hepatitis C, Chronic studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 7Phase 2 7Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected PatientsCompletedNCT02176525Phase 1Results posted
• BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3CompletedNCT01830127Phase 2Results posted
• IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1CompletedNCT01732796Phase 3Results posted
• Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2CompletedNCT01728324Phase 3Results posted
• Drug-drug Interaction of BI 201335 and MicrogynonCompletedNCT01570244Phase 1Results posted
• This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedNCT01528735Phase 2Results posted
• Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedNCT01525628Phase 1Results posted
• Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedNCT01399619Phase 3Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedNCT01358864Phase 3Results posted
• Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedNCT01132313Phase 2Results posted
• 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV PatientsCompletedNCT00905632Phase 1Results posted
• Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -ExperiencedCompletedNCT00793793Phase 1Results posted
• Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)CompletedNCT00774397Phase 2Results posted
• Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT02254707Phase 1/2
• Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT02226952Phase 1/2
• Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis CCompletedNCT02226939Phase 2
• Open Label Trial to Compare BI 207127 to Telaprevir in HCV PatientsWithdrawnNCT01858961Phase 3
• A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C InfectionWithdrawnNCT01608737Phase 3